()
 
 

Overview

Lixte is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, the Company develops new chemotherapy drugs targeting molecular abnormalities of common human cancers. Over the past year, based on the discovery of a new biomarker for brain cancers by collaborators at NIH, the Company is developing new drugs for the treatment of glioblastoma multiforme (GMB), the most common and most aggressive type of primary brain cancer in adults and, to a much lesser extent, in children.


Contact Information

248 Route 25A
No. 2
East Setauket, NY 11733

tel: 631-942-7959
fax:


,  



Investor Relations



tel:
fax:




Stock

Exchange: OTCBB
Industry: Unknown
Market Cap: $22.2M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.